Novartis launches strategic review of Sandoz

29 October 2021 - Deborah Wilkes


Novartis has launched a strategic review of its Sandoz generics division, including its OTC operations, with options ranging from “retaining the business to separation”.

Click tags below for more information on topics:

Novartis Sandoz

Annual Subscription Holder?

Sign in to continue reading.

Sign In

Back to Industry News

Share this page: